Gene-modified dendritic cells (DC) provide unique therapeutic strategies for prostate cancer; however, the comparative evaluation of specific delivery options using appropriate preclinical models has not been described. In this study, bone marrow-derived DC were genetically engineered to express high levels of interleukin-12 (IL-12) with or without the costimulatory molecule B7-1, by ex vivo infection with recombinant adenoviral vectors. We used an orthotopic metastatic mouse prostate cancer preclinical model (178-2 BMA) to compare two therapeutic protocols for DC delivery, in situ and subcutaneous. DC were generated from bone marrow of syngeneic 129/ Sv mice by culturing in the presence of GM-CSF and IL-4. In vitro DC/IL-12 or DC/IL-12/B7 produced high levels of biologically active IL-12. In situ delivery of DC/IL-12 or DC/IL-12/B7 induced a significant suppression of primary tumor growth compared to DC/bgal controls (P ¼ .0328 and P ¼ .0019, respectively), as well as reduced numbers of spontaneous lung metastatic nodules (P ¼ .1404 and P ¼ .0335, respectively). In survival experiments, in situ DC/IL-12 injection demonstrated a small but statistically significant advantage (P ¼ .0041). Subcutaneous, tumor lysate pulsed DC/IL-12 significantly decreased tumor size (P ¼ .0152) and increased survival (P ¼ 0.0433) compared to HBSS controls but the decrease in the number of spontaneous lung metastases did not achieve statistical significance. Both in situ and subcutaneous treatments enhanced cytolytic activities of natural killer (NK) cells and cytotoxic T lymphocytes (CTL). In this preclinical model, gene-modified DC-based intratumoral immunotherapy was shown to be an effective therapeutic strategy for locally advanced prostate cancer based on tumor growth suppression, inhibition of metastasis and survival improvement.
H uman 1 and mouse 2, 3 prostate cancer cells are generally considered to be poorly immunogenic despite the presence of antigens that may be organ and/ or tumor specific. 4 This lack of immune stimulation may be overcome by enhancing the function of antigenpresenting cells (APC). Dendritic cells (DC) are potent APC that can both elicit primary and secondary immune responses. [5] [6] [7] A number of clinical trials have been initiated using dendritic cells isolated from the peripheral blood of prostate cancer patients primed with specific polypeptides or tumor RNA/protein, however, these strategies require considerable technical support. 8 DC pulsing with tumor antigens is an alternative strategy, yet it may be difficult to obtain adequate amounts of tumor tissues of high enough purity in patients with locally advanced prostate cancer.
Stimulation of an antitumor immune response by DC is critically dependent on their tightly regulated ability to produce interleukin-12 (IL-12). IL-12 is a key cytokine in the induction of the Th-1-type immune response, and the use of IL-12 in combination with DC enhances specific cytotoxic T lymphocyte (CTL) induction in vitro 9 and in vivo. 10 However, administration of IL-12 systemically has resulted in significant toxicity in both preclinical studies and human trials. An alternative approach is to deliver gene-modified DC that are transduced ex vivo with the IL-12 gene directly to the site of the tumor. Several reports [11] [12] [13] demonstrated that intratumoral injection of DC genetically modified to express IL-12-induced systemic antitumor immunity through the induction of tumor-specific CTL in other nonprostate murine subcutaneous tumor models. DC injected intratumorally are capable of capturing tumor antigens in situ at the tumor site, migrating to regional lymph nodes, and inducing a subsequent systemic immune response against the tumor, even without antigen loading.
14 Enhanced IL-12 expression and secretion could enhance and sustain DC functions and promote the activities of other immune cells, for example, CD4 þ T cells. In addition, the approach of intratumoral injection would offer the potential advantage of augmenting a broader T-cell immune response to tumor-associated antigens that would not be obtained by pulsing DC with several defined peptides.
In this study, bone marrow-derived DC were genetically engineered to produce high levels of IL-12 with or without the costimulatory molecule B7-1 by ex vivo infection with recombinant adenoviral vectors (AdmIL-12 or AdmIL-12/B7). We evaluated the capacity of direct intratumoral (in situ) injection of DC/IL-12 and DC/IL-12/B7 to elicit antitumor responses in vivo in a mouse orthotopic model with poorly immunogenic prostate cancer cells (178-2 BMA) as a preclinical model of prostate cancer. The 178-2 BMA orthotopic model is characterized by aggressive tumor growth and spontaneous metastasis to the bone and various soft-tissue sites including lung. We compared this approach with subcutaneous delivery of DC/IL-12 pulsed with cancer cell lysates in mice with orthotopic tumors with regard to local tumor growth, incidence of metastasis, host survival and induced systemic cytolytic T-cell activities.
Materials and methods

Adenoviral vectors
The adenoviral vectors (AdmIL-12 and AdmIL-12/B7) were kindly provided by Dr Frank Graham of McMasters University (Ontario, Canada). The recombinant adenoviruses were isolated from a single plaque, expanded in 293 cells, and purified by double cesium-gradient ultracentrifugation. Virus titers were determined by plaque assay and reported as PFUs. As a control adenoviral vector, Adbgal was prepared as described previously. 2 
Mice
Male 129/Sv mice were used at 12-16 weeks of age. All mice were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care, and all animal studies were conducted in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals.
Cell lines and culture
Mouse prostate cancer cell line 178-2BMA was derived from a bone metastasis that developed in vivo from a ras þ myc-initiated, p53 null primary mouse prostate cancer using the mouse prostate reconstitution model system in 129/Sv mice. [15] [16] [17] This cell line reproducibly metastasizes to bone, lymph nodes, and lung following orthotopic inoculation. The cells were routinely cultured in DMEM supplemented with 10% FBS in a humidified atmosphere of 5% CO 2 at 371C.
Generation of DC in vitro from bone marrow
The procedure used in this study was described previously, 18 with minor modifications. Briefly, bone marrow was flushed from femurs and tibias and depleted of erythrocytes with ACK lysing buffer (Biosourse International, Camarillo, CA). Bone marrow cells were depleted from lymphocytes, granulocytes, and Ia þ cells using a mixture of monoclonal antibody and rabbit complement. The monoclonal antibodies were 2.43 (anti-CD8), GK1.5 (anti-CD4), RA3-3A1/6.1 (anti-B220/CD45R), and B21-1 (anti-Ia; TIB 210, 207, 146, and 229, respectively; ATCC). Cells were plated in six-well culture plates (3.5 Â 10 6 cells/ well) in RPMI 1640 supplemented with 10% heatinactivated FBS, antibiotic-antimycotic solution, recombinant murine granulocyte/macrophage colony-stimulating factor (20 ng/ml; R&D systems, Minneapolis, MN) and recombinant murine IL-4 (100 ng/ml; R&D systems, Minneapolis, MN). Fresh medium was added every other day. On day 7, nonadherent cells and loosely adherent proliferating DC aggregates were collected and replated.
Infection of DC with adenoviral vectors
Transduction of DC with adenoviral vectors was performed on day 7. DC were infected with AdmIL-12 (DC/ IL-12), AdmIL-12/B7 (DC/IL-12/B7) or Adbgal (DC/ bgal) at moi's of 100, 1000, 3000, or 5000 using serum-free RPMI 1640. After 2 hours, DC were centrifuged and replated with RPMI 1640 supplemented with 10% heatinactivated FBS in 24-well plates or 100-mm dishes. Triplicate wells were counted 24 and 48 hours after transduction to evaluate for direct cytotoxicity of the vectors. For determination of secreted IL-12 levels from gene-modified DCs in vitro, DCs were cultured without or with 178-2BMA cancer cells for 48 hours then the medium was collected and assayed for murine IL-12 by ELISA (BioSource International, Camarillo, CA). Tumor lysates were prepared by subjecting 178-2 BMA cells to four or five freeze/thaw cycles with lysis monitored by phase-contrast microscopy. Larger particles were removed by centrifugation (15 minutes, 500xg), and the supernatants were passed through a 0.2 mm filter. The resulting tumor lysates were stored at À801C in aliquots until use. On day 8 of culture DC, DC/bgal or DC/IL-12 (1 Â 10 6 ) were pulsed with tumor lysates (3 Â 10 6 cancer cell equivalents) for 14 hours.
Flow cytometric analysis
DC were analyzed for expression of cell surface markers on either day 8, 1 day after infection with AdmIL-12, AdmIL-12/B7, or Adbgal, or day 9, 1 day after pulsing with tumor lysate DC alone or DC/bgal or DC/IL-12. The cells were collected and incubated for 30 minutes with FITC-conjugated anti-mouse MHC class II, CD11c, B7-1, or B7-2 antibodies (PharMingen, San Diego, CA) then washed and 10,000 cells analyzed on an EPICS XL-MCL (Coulter Electronics, Westbrook, ME) and the mean fluorescence intensity (MFI) reported. 
In vivo therapy -intratumoral injection
At day 7 after the orthotopic tumor cell inoculation, 1x10 6 of DC transduced at moi 3000 were injected directly into the orthotopic tumors. A 30-gauge needle was placed through an intracapsular, transprostatic tract prior to tumor penetration to minimize leakage of virus at the time of needle withdrawal. The needle point was then moved around within the tumor during injection to maximize the area infiltrated by DC. A volume of o25 ml was used for all DC injections. Animals were euthanized on the 21st day after tumor inoculation or at indicated time points. For survival analysis, animals were evaluated at death, or euthanasia when appearing in distress, as evidenced by lethargy, ruffled fur, or weight loss. All animals underwent a careful necropsy for gross metastasis. The primary tumor and spleen were removed and weighed. Lungs were fixed in Bouins' solution and lung metastases counted with a dissecting microscope. Samples of tissue were placed in formalin, paraffin embedded, cut into 4-5-mm sections, and stained with H&E for histological examination or immersed in Tissue-Tec OCT medium and quick frozen in liquid N 2 .
In vivo therapy -subcutaneous injection
On day 3 after the orthotopic tumor inoculation, 1 Â 10 6 of tumor lysate pulsed DC/IL-12, pulsed DC/bgal, pulsed DC or HBSS were subcutaneously injected into the right flank. Animals were evaluated as described above.
Cytolytic assays
NK cell lytic activity was measured in spleen cells harvested from the different treatment groups at day 3 after DC injection. NK activity was determined with 51 Crlabeled YAC cells as the target cells as previously described.
2 CTL assays were performed 7 days after the DC subeutaneous injection (14 days after the tumor inoculation). The spleen cells from treated mice (1.8 Â 10 7 cells/well) were cocultured with irradiated (10,000 rad) 178-2 BMA cells (15:1 responder:tumor cell ratio) in 4 ml of complete T-cell medium (RPMI 1640 containing 50 mM 2-mercaptoethanol) with 10% heat-inactivated FBS at 371C in a humidified atmosphere containing 5% CO 2 . One day after culture initiation, mouse IL-2 (R&D systems, Minneapolis, MN) was added to the cultures to yield final concentrations of 20 U/ml. Cytotoxic effector lymphocytes were harvested after 5 days of incubation and used in a standard 51 Cr release assay to test the cytolytic activity of the effector cells. Target cells (178-2 BMA cells) were labeled with 51 Cr and incubated with effector cells at 371C in 5% CO 2 for 4 hours at various E:T ratios. Supernatants were obtained after incubation and subjected to gamma counting. The maximum or spontaneous release was defined as counts from samples incubated with 10% SDS or medium alone, respectively. Cytolytic activity was calculated using the following formula: percentage of specific 51 Cr release ¼ (experimental release Àspontaneous release) Â 100/(maximum release Àspontaneous release). Assays were performed in triplicate wells. The spontaneous release of all assays was o20% of the maximum release.
In vitro induction of CTL with pulsed DC Spleen cells were obtained from orthotopic tumor-bearing mice at 7 days after tumor inoculation and were cocultured with unpulsed DC, pulsed DC, pulsed DC/ bgal, or pulsed DC/IL-12 (15:1 responder:DC ratio) as described above. Induced cytotoxic effector lymphocytes were harvested after 6 days of incubation and used in the cytolytic assay with 178-2 BMA cells as targets.
Statistical analysis
Unpaired t-test was used to compare tumor weight and metastatic activity. Survival analysis was with the logrank test (Mantel-Cox test). All statistical analyses were performed with Statview 5.0 (Abacus Concepts, Berkeley, CA).
Results
Phenotypic characteristics of transduced DC
Lymphocyte-depleted bone marrow cell suspensions were cultured for 7 days with GM-CSF and IL-4 yielding cultures of 70-90% pure DC according to the combined immunostaining for MHC class II, CD11c, CD80 and CD86 expression (data not shown). DC were transduced with an adenoviral vector expressing IL-12 gene without or with the costimulatory molecule B7-1 (AdmIL-12 or AdmIL-12/B7). The concentration of mIL-12 released into the culture media 48 hours after transduction was measured by ELISA without or with 178-2 BMA cancer cell coculture (Fig 1) . A dose-dependent increase in IL-12 secretion was seen in the AdmIL-12 transduced DC and coculturing these DC with cancer cells enhanced the secretion of IL-12. AdmIL-12/B7 transduced DC also secreted IL-12 in a dose-dependent manner. DC transduced with Adbgal at a high moi secreted low levels of IL-12 that were unaffected by cancer cell coculture. Based on these results, we selected moi 3000 for subsequent studies. Cell viability in 48 hours after the viral infection with 3000 moi of AdmIL-12 was 80-90% of nontransduced DC, but was reduced to approximately 50% with AdmIL-12/B7.
The expression of costimulatory molecules (CD80 and CD86) and MHC class II was analyzed by FACS and IL-12 gene-modified DC for prostate cancer T Saika et al expressed as the mean fluorescent intensity (MFI) for each DC population (Table 1) . DC/IL-12/B7 expressed increased amounts of costimulatory molecules (CD80 and CD86) and MHC II in comparison with DC/IL-12, while DC/IL-12 showed increased levels of these surface molecule compared to nontransduced DC or DC/bgal (Table 1) . Increased staining intensity CD80 and CD86 was also seen in DC/IL-12 treated with tumor lysate, Interestingly, the increased levels of CD80 and CD86 were comparable to those induced in DC/IL-12/B7 (Table 1) .
Therapeutic responses to transduced DC
We used a preclinical prostate cancer model to evaluate the effect of two routes of administration of genemodified DC on suppression of orthotopic tumor growth, metastatic dissemination, and prolongation of survival. Orthotopic tumors were initiated by injecting 5000 cells of the 178-2 BMA mouse prostate cancer cell line into the right dorsal lateral lobe of the prostate. This model provides uniform and reproducible tumor growth and metastasis. 15 Routes of administration evaluated as treatment strategies were direct intratumoral (in situ) injection 7 days after tumor initiation or subcutaneous injection 3 days after tumor initiation. For the subcutaneous route of delivery the transduced DCs were also pulsed with tumor lysate. At 3 weeks after tumor initiation the therapeutic response was evaluated in terms of orthotopic tumor weight (Fig 2a) or number of lung metastases (Fig 2b) . Direct, in situ, injection of gene modified DCs produced a significant reduction of tumor weight (Fig 2a) . In comparison with DCs transduced Adbgal, both AdmIL-12 and AdmIL-12/B-7 suppressed tumor weight at the time of sacrifice (P ¼ .0328 and P ¼ .0019, respectively). Although the reduction of tumor weight with DC/IL-12/ B7 was more pronounced than with DC/IL-12 this difference did not achieve statistical significance (P ¼ .1013). Subcutaneous delivery of tumor lysate pulsed DC/IL-12 produced a significant reduction in tumor size compared with a control group of HBSS injection (P ¼ .0152; Figure 2a) . Although subcutaneous delivery of tumor lysate pulsed DC or DC/bgal reduced the orthotopic tumor weight compared to subcutaneous Figure 1 Secreted IL-12 in transduced DC. DC were infected with the indicated adenoviral vector at an moi of 0, 100, 1000, 3000, or 5000 and were seeded in 24-well plates without or with 178-2 BMA cells. Medium from triplicate wells were collected, and the level of IL-12 determined by ELISA then corrected for the number of dendritic cells (Bars, SD). Figure 3b ). Subcutaneous DC/bgal did not significantly improve survival compared to HBSS control group (P ¼ .1907).
NK activity
Splenocytes were harvested from mice with orthotopic tumors 3 days after either in situ or 4 days after subcutaneous treatment and evaluated for NK activity by lytic activity against YAC cells (Fig 4) . In situ DC/IL-12 demonstrated the highest level of activity but this did not achieve statistical significance (P ¼ .2168). NK activities returned to control levels by day 7 or 11 (data not shown).
CTL activities
We initially performed an evaluation of the ability of gene modified, tumor lysate-pulsed DC to present tumor antigens to splenocytes and generate tumor cell specific cytolytic activities in vitro (Fig 5a) . Spleen cells were obtained from mice bearing 178-2 BMA orthotopic tumors and co-cultured with DC in the presence of IL-2. After 6 days in vitro the splenocytes were used in a chromium release assay with 178-2 BMA cancer cells as targets. Only tumor-lysate pulsed DC/IL-12 were capable of generating tumor-specific cytolytic cells whereas tumor-lysate pulsed DC/bgal, pulsed DC or unpulsed DC did not induce tumor-specific cytolytic cells.
Splenocytes harvested from mice with orthotopic tumors treated with intratumoral injections of both DC/IL-12 and DC/IL-12/B7 demonstrated increased levels of lytic activity against 178-2 BMA cancer cells on day 7 after treatment (i.e. 14 days after tumor initiation) compared with control splenocytes from mice with orthotopic tumors treated with intratumoral injection of DC/bgal (Fig 5b) . At an effector IL-12 gene-modified DC for prostate cancer T Saika et al to target ratio of 100:1 these differences were statistically significant (P ¼ .0113 for DC/IL-12 and P ¼ .0123 for DC/ IL-12/B7). Splenocytes harvested from mice with orthotopic tumors treated with subcutaneous injection of pulsed DC/IL-12 also demonstrated increased levels of lytic activity against 178-2 BMA cancer cells on day 11 after treatment (i.e. 14 days after tumor initiation) compared with control splenocytes from mice with orthotopic tumors treated with subcutaneous injection of pulsed DC/bgal (P ¼ .0043 at 100:1, Fig 5c) .
Discussion
We previously reported that in situ adenoviral vectormediated IL-12 gene therapy was effective in a preclinical model for prostate cancer that was similar to the model used for the studies reported here. 2, 19, 20 Further, we demonstrated that in situ adenoviral vector-mediated IL-12 combined with B7-1 gene therapy was significantly more effective in delaying orthotopic tumor growth and inducing partial or complete regression than adenoviral vector-mediated IL-12 alone. 19 Since DC are potent professional APC with the capacity to induce tumorspecific CTL activity and potent antitumor effects, we reasoned that IL-12 gene-modified DC may offer an alternative and potentially more potent immuno-gene therapy by providing enhanced APC functions. 21, 22 Consistent with other reports, 13, 23 we needed a high moi of adenoviral vector to achieve significant IL-12 secretion by DC (see Fig 1) . We therefore chose an moi of 3000 as our working condition of infection. The requirement for high vector titers to achieve efficient gene transfer suggest that DC lack the adenovirus attachment factor Coxsackie-adenovirus receptor (CAR) or the alpha V integrins, alpha V beta3 or alpha V beta 5, used by the virus for fusion with its target cell. 24, 25 To improve gene transfer efficiency and expression level, several approaches have been reported such as using poly-L-lysine, transferin, lipofectamine, or centrifugal manipulation. [26] [27] [28] [29] Those methods were not introduced in the current study to avoid additional complexity but they could be considered as alternatives in future studies.
The principal host immune response against cancer cells is a Th1 cellular response. Requirements for this response include immunogenic tumor cell antigen expression, uptake, and presentation by professional APC of the immune system, for example, macrophage and dendritic cells, and appropriate and sustained downstream immune cell responses. Tumor antigenicity may be enhanced by initiating expression of antigenic molecules or by increasing the efficiency of antigen presentation. In the rare situation where specific tumor antigens are known they may also be expressed in APC. DC can be isolated from patients and modified to present tumor antigens and express cytokines or costimulatory molecules. In addition, it has been shown that DC pulsed with peptide of tumorassociated antigens, whole cell lysates, or RNA can trigger tumor-specific responses. [30] [31] [32] These approaches are currently limited in prostate cancer due to the lack of defined tumor antigens; the technical difficulties in obtaining sufficient amounts of mRNA; and limitations The T-cell stimulatory capacity of DC correlates with increased surface expression of MHC II and costimulatory molecules. 33 The upregulation of costimulatory molecules and MHC I/II of DC could enhance the immunogenicity of tumor antigens in poorly immunogenic cancers such as prostate cancer that are otherwise not recognized by immune system. With this in mind, we transduced DC with IL-12 and costimulatory factor B7-1 gene and confirmed increased secretion of IL-12 (Fig 1) and upregulation of both CD80 and CD86 expression (Table 1) . It is notable that pulsing DC/IL-12 with tumor lysate also led to upregulation of both B7-1 and B7-2 to levels that were comparable to those resulting from expression of exogenous B7-1 ( Table 1 ). The upregulation of both CD80 and CD86 has also been observed in DC transduced with an adenoviral vector expressing the Rel homology domain of NFkB. 34 Significantly increased MHC class II was only seen in the DC/IL-12/B7 group (Table 1) . Curiously, in vivo CTL activities in this study showed no difference between DC/IL-12 group and DC/ IL-12/B7 group. Intratumoral injection of DC/IL-12/B7 did result in the lowest average tumor weight and the fewest average number of lung metastatic nodules and some longer-term survivors. However, in the in situ treatments, we did not detect a statistical difference between DC/IL-12 and DC/IL-12/B7 in local tumor growth inhibition, suppression of lung metastases, or survival.
Our assessment of CTL activities in both direct in situ delivery of IL-12-transduced DC versus subcutaneous IL-12-transduced DCs indicated that this response was comparable. However, our previous data indicated that direct delivery of adenoviral vector-mediated IL-12 to tumor cells resulted in significantly increased immune cell infiltration that included macrophages and T cells. 2, 19 The delivery of DC that had been transduced with the IL-12 gene would likely enhance the immune cell infiltration produced by in situ AdmIL-12 injection as CD4 T cells may continue to activate DC for extended periods of time and propagate a prolonged immune cell infiltration that could be more effective in propagating T-cell activities, including a CTL. These enhanced activities may be, in part, responsible for the increased tumor growth suppression of in situ DC/IL-12 delivery compared to subcutaneous DC/IL-12 delivery. It is also possible that more efficient antigen uptake by DC occurs within the tumor following in situ injection of modified DCs than in vitro with tumor lysate or that specific antigens present within the tumor milieu are more immunogenic than those present in tumor lysates. Further studies to address this question are warranted.
Overall, the basic objective of our study was to determine the comparative efficacy of in situ intratumoral delivery of adenoviral vector-mediated IL-12 gene-modified DC compared to subcutaneous adenoviral vectormediated IL-12-transduced tumor lysate pulsed DC in a relevant preclinical orthotopic model for metastatic prostate cancer. The results indicated that direct in situ delivery of IL-12-transduced DC was moderately more effective than the subcutaneous route of administration. This conclusion is supported by enhanced local growth suppression, reductions in spontaneous metastatic activities and, importantly, a significant increase in the survival of animals treated with in situ IL-12-transduced DC compared to subcutaneous IL-12 transduced DC relative to b-gal controls for either delivery approach. Our results also indicated overlap in cellular mechanisms underlying this therapeutic response in that both in situ and subcutaneous protocols increased NK activity and generated CTL responses that were comparable in nature.
Clinically, the delivery of gene-modified DC directly into the prostate compared to subcutaneous delivery would not pose any dilemma. Our previous studies using direct injection of adenoviral vectors that transduced the therapeutic HSV-tk therapeutic gene indicate that this procedure is safe and can be effectively accomplished. 35 Thus, the results of our studies suggest that an extension of this clinical protocol using IL-12-transduced DC or other gene-modified DC in a similar procedure should be pursued.
